Introduction
CD34+ hematopoietic stem and progenitor cells are critical to cell therapy development, gene editing workflows, and translational immunology research. Whether sourced from bone marrow, mobilized peripheral blood, or cord blood, CD34 cell quality and documentation directly influence downstream expansion, differentiation, and functional outcomes.
In 2026, research teams are evaluating suppliers based not only on availability, but also on donor screening transparency, isolation methodology, documentation standards, and logistical reliability.
This comparison reviews leading CD34 cell suppliers serving academic, biotech, and translational research programs.
Disclosure: This article was developed by CGT Global, a supplier of CD34+ cells and related donor-derived products. Vendors were evaluated using publicly available information and general industry knowledge as of October 2025. This is not an exhaustive list of all global suppliers.
Why CD34 Cell Source Matters
CD34+ cells may be derived from:
• Mobilized peripheral blood leukopaks
• Bone marrow aspirates
• Umbilical cord blood
Each source affects:
• CD34 yield and purity
• Donor variability
• Expansion potential
• Processing complexity
• Regulatory documentation requirements
When comparing suppliers, consider:
• Donor screening and infectious disease testing
• Isolation and enrichment methodology
• Documented purity and viability ranges
• Traceability and available documentation
• Fresh versus cryopreserved format options
• Scheduling and collection logistics
Capabilities and documentation levels vary by vendor and product type. Researchers should confirm specifications directly with suppliers before purchase.
Top CD34 Cell Suppliers for 2026
1. CGT Global
Best for: Custom mobilized CD34 collections with flexible sourcing options, bulk isolations
CGT Global provides CD34+ cells derived from mobilized peripheral blood, bone marrow, and cord blood under IRB-approved donor programs. Products are available in fresh and cryopreserved formats depending on project requirements.
Each lot includes documentation detailing donor screening, infectious disease testing, and cell characterization metrics.
Key Features
• Multiple CD34 source options, including mobilized peripheral blood, bone marrow, and cord blood
• In house hospital staff collecting cord blood samples with immediate processing at a nearby facility to help preserve cell viability
• Custom donor selection criteria tailored to program requirements
• Documented purity and viability metrics provided with each lot
• Flexible fresh and cryopreserved format options
• Direct scientific communication and coordinated scheduling support
CGT Global provides customizable sourcing options and competitive pricing depending on donor and format requirements.
2. STEMCELL Technologies
Best for: Standardized research workflows
STEMCELL Technologies provides CD34+ cells optimized for use within their reagent and expansion platforms. These products are typically used in academic and discovery research settings.
3. Lonza
Best for: Established commercial bioprocessing workflows
Lonza offers CD34+ cells and related hematopoietic products used in research and preclinical programs. Their portfolio supports broader cell therapy development workflows.
4. BioIVT
Best for: Translational research programs
BioIVT provides CD34+ cells sourced from mobilized donors and cord blood with supporting donor documentation.
5. iXCells Biotechnologies
Best for: Customized donor requests
iXCells provides tailored CD34+ isolations based on specified donor characteristics and research needs.
Pricing Considerations
CD34+ cell pricing varies significantly depending on:
• Source type
• Enrichment method
• Purity level
• Donor selection criteria
• Fresh versus cryopreserved format
• Testing and documentation requirements
Publicly listed pricing, where available, represents base product cost and may exclude shipping, processing, testing, or contractual discounts.
Researchers should request formal quotes to compare total project cost accurately.
FAQs
What purity should I expect for CD34+ cells?
Purity levels vary based on enrichment method and source. Many suppliers provide documented purity ranges with each lot.
Is mobilized peripheral blood better than bone marrow?
Mobilized peripheral blood often yields higher CD34 counts, while bone marrow may offer different biological characteristics. Selection depends on project goals.
Can I obtain fresh CD34+ cells?
Some suppliers offer fresh collections based on scheduling availability. Lead times depend on donor matching and logistics.
Are CD34+ cells available under GMP conditions?
Some vendors support GMP-aligned or clinical-grade programs. Requirements vary by supplier and intended use.
How These CD34+ Cell Suppliers Were Evaluated
This comparison was developed by CGT Global, a supplier of CD34+ cell products. The purpose of this article is to provide an educational overview of supplier considerations for research and translational programs.
Inclusion Criteria
Suppliers were included if they:
• Publicly market CD34+ cell products
• Offer mobilized peripheral blood, bone marrow, or cord blood sources
• Serve research or translational programs
• Provide sufficient information regarding source type, enrichment method, or documentation
This list is not exhaustive and does not include every global CD34+ supplier.
Evaluation Factors
Suppliers were evaluated across:
• Source type options available
• Enrichment methodology transparency
• Documented purity and viability ranges
• Donor screening and traceability standards
• Fresh versus cryopreserved availability
• Stated customer support structure
No supplier was evaluated using proprietary or confidential competitor information.
Data Sources
Information was compiled from publicly accessible vendor materials, scientific literature where relevant, and general industry knowledge related to hematopoietic cell sourcing.
Suppliers were not independently audited for this comparison.
Pricing References
Where pricing is discussed, it reflects publicly listed information when available at the time of writing.
If pricing is not publicly available, cost is described qualitatively rather than numerically.
Final pricing may vary based on source type, enrichment method, donor criteria, testing requirements, shipping, volume agreements, and program scope.
Service and Responsiveness
Support descriptions reflect publicly stated communication channels. Response time estimates are not independently verified unless otherwise specified.
Editorial Nature of Rankings
Final positioning reflects an editorial assessment based on the criteria above and may not reflect every research use case or development stage.
Last updated: October 2025
Conclusion
The CD34+ supplier landscape in 2026 is shaped by flexibility, documentation, and logistical coordination. Source type, donor variability, and processing methodology all influence downstream performance.
CGT Global provides customizable CD34+ sourcing options across mobilized, bone marrow, and cord blood formats, with documented donor screening and responsive coordination. Researchers should evaluate suppliers based on transparency, scheduling flexibility, and alignment with their program requirements.
Pricing and product specifications referenced in this article were based on publicly available information as of October 2025 and may have changed.
